Why the study?
Viral replication has been the central focus for antiviral drug development, prompting evaluation of RdRp inhibitor analogues across various viral diseases to treat COVID-19.
RdRp inhibitors developed for other viral diseases represent potential therapeutic candidates for COVID-19.
This is the authors' abstract. We don't add key points for this paper.
) computational approach. From the beginning, viral replication has been the main focus for any antiviral drug development for viral diseases, including HCV, influenza virus, zika virus, norovirus, measles, dengue virus, and coronaviruses. This review lists the nucleoside, nucleotide, and non-nucleoside RdRp inhibitor analogues of various viral diseases that may be evaluated for drug development to treat COVID-19.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for RdRp inhibitor repurposing in COVID-19; does not support practice change without prospective trials.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: